CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer
March 17 2022 - 6:30AM
Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused
on generating data-driven insights to diagnose, understand, and
treat rare diseases, announced an expansion of the Company’s data
access and collaboration agreement with Pfizer Inc. The initial
agreement, which granted Pfizer access to data of interest from
CENTOGENE’s Bio/Databank, was established in 2019 to advance the
discovery and validation of novel genetic targets as candidates for
the development of new therapies for rare diseases.
A new collaborative research project has now been initiated,
which may be used to validate rare genetic causes of
neurodegenerative diseases as potential targets for specific
diseases. Data will be generated based on an existing cohort of
patient samples from CENTOGENE’s Bio/Databank.
Dr. Patrice Denèfle, Chief Scientific Officer at CENTOGENE,
said, “Establishing an additional collaborative research project
with Pfizer underscores the value we believe our Bio/Databank may
bring to data-driven discovery in rare diseases R&D. With our
Bio/Databank, extensive cohorts from clinical studies, and diverse
global diagnostic footprint, CENTOGENE is uniquely positioned to
discover potential roadmaps for neurodegenerative diseases that may
be linked to rare genetic factors. This new phase in our research
collaboration project is a milestone achievement for innovative
data-driven drug discovery and development that may help in
delivering breakthrough treatments to patients.”
CENTOGENE’s unique Bio/Databank integrates relevant structured
and unstructured patient-consented data, including clinical
information, health records, and multiomic data, including genetic,
transcriptomic, proteomic, and metabolomic insights. It also
includes longitudinal data, such as biomarkers and patient recorded
outcomes, as well as diagnostic workflow data. Individual-level
data is managed, protected, and shared in compliance with
international data privacy regulations.
About CENTOGENE
CENTOGENE engages in diagnosis and research around rare diseases
transforming real-world clinical, genetic, and multiomic data to
diagnose, understand, and treat rare diseases. Our goal is to bring
rationality to treatment decisions and to accelerate the
development of new orphan drugs by using our extensive rare disease
knowledge and data. CENTOGENE has developed a global proprietary
rare disease platform based on our real-world data repository of
over 600,000 patients representing over 120 different
countries.
The Company’s platform includes epidemiologic, phenotypic, and
genetic data that reflects a global population, as well as a
biobank of patients’ blood samples and cell cultures. CENTOGENE
believes this represents the only platform focused on comprehensive
analysis of multi-level data to improve the understanding of rare
hereditary diseases. It allows for better identification and
stratification of patients and their underlying diseases to enable
and accelerate discovery, development, and access to orphan drugs.
As of December 31, 2020, the Company collaborated with over 30
pharmaceutical partners.
Follow us on LinkedIn
Forward-Looking Statement
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative worldwide economic conditions and ongoing instability and
volatility in the worldwide financial markets, the effects of the
COVID-19 pandemic on our business and results of operations,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, our reliance on third parties and collaboration
partners, including our ability to manage growth and enter into new
client relationships, our dependency on the rare disease industry,
our ability to manage international expansion, our reliance on key
personnel, our reliance on intellectual property protection,
fluctuations of our operating results due to the effect of exchange
rates, our ability to streamline cash usage, our requirement for
additional financing and our ability to continue as a going
concern, or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on April 15, 2021,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Contacts:
Ben LeggCorporate CommunicationsPress@centogene.com
Lennart StreibelInvestor
RelationsInvestor.Relations@centogene.com
Stern IR Brendan Payne+1 (212) 698
8695Brendan.Payne@sternir.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Sep 2023 to Sep 2024